CHARISMA May Make Bayer Primary MI Prevention Petition More Popular
This article was originally published in The Tan Sheet
Executive Summary
Bayer's bid for an indication for the primary prevention of MI on professional aspirin labeling may be strengthened by data from the CHARISMA trial